News & Updates

Learn about the latest company updates and industry news

Company News2023-7-17

HeartRhythm secures nearly 100 million yuan in Series A funding to fully establish a mechanical circulatory support technology platform for heart failure.

Shanghai Dynaheart Medical Technology Co., Ltd. (Dynaheart) recently closed nearly 100 million RMB in Series A funding, led by IDG Capital with participation from Huage Capital and Langmachang Capital. The funds will be primarily used for the regulatory clinical trials of its flagship product, OmniHeart Percutaneous Ventricular Assist Device, as well as accelerating the R&D, clinical development, and commercialization of its existing product line and new initiatives.

Company News2024-1-16

OmniHeart® Percutaneous Ventricular Assist Device Registration Study

The OmniHeart® Percutaneous Ventricular Assist Device demonstrated favorable safety and efficacy in preclinical animal studies and a First-in-Human (FIH) trial. This registered clinical trial evaluates the safety and efficacy of the device for high-risk PCI patients to support its regulatory submission and market approval in China.

Academic Achievements2025-7-8

ICC&CRCC2025||Focus on OmniHeart® 4.0 Percutaneous Left Ventricular Assist Device

"New Research, New Developments, and New Achievements" is the theme of the 20th Cold-Region (Ice City) Cardiovascular Conference. Upholding this mission, OmniHeart® 4.0 Percutaneous Left Ventricular Assist Device held a dedicated symposium on research progress, witnessed by numerous clinical experts.

Company News2024-1-16

Exciting news! Dynaheart Medical has been featured on the 2023Venture50 list.

On 2024/1/16, the results of the 2023Venture50 awards, initiated by Qingchuang Venture Capital (1945.HK) and Investment Universe, were finally announced! Dynaheart Medical, an innovative company in the heart failure field, has made it onto the list.

Company News2024-4-19

Dynaheart Medical's Implantable Left Ventricular Assist Device Receives Approval as an Innovative Medical Device

On 2024/4/19, the National Medical Products Administration's Center for Medical Device Evaluation announced the results of its "Green Channel" review for 2024 Issue No. 4. The Dynaheart Medical Transcatheter Left Ventricular Assist System has been approved as an innovative medical device and entered the special review process. Developed independently by Dynaheart Medical, this system boasts full proprietary intellectual property rights and offers significant advantages across multiple dimensions, marking another major milestone in China's domestic high-end medical devices!